Biofrontera Inc. BFRI 深 沪
等待开盘 10-07 09:30:00 美东时间
0.932
+0.041
+4.61%
华盛通- 最 高0.9478
- 今 开0.88
- 成交量 39.03万股
- 最 低 0.86
- 昨 收 0.8909
- 总市值 1384.24万
- 52周最高 1.66
- 市盈率 静 --
- 换手率 2.63%
- 52周最低 0.5547
- 委 比 10.53%
- 总股本 1485.24万
- 历史最高 292.60
- 量 比 1.00
- 振 幅 9.86%
- 历史最低 0.536
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Transcript: Biofrontera Q2 2026 Earnings Conference Call
On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access the full call at...
09-28 20:47
Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults
With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a pre-cancerous skin condition, actinic keratosis (AK), and a skin cancer. The sBCC indication expands the addr...
09-14 21:31
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Ameluz, a photodynamic therapy (PDT) drug, has been approved by the FDA in combination with the RhodoLED lamp to treat superficial Basal Cell Carcinoma (sBCC) in adults, making it the first and only PDT approved for skin cancer in the U.S. This expands Ameluz's market potential and strengthens its role in medical dermatology. The approval follows a successful Phase 3 trial showing high efficacy rates, and Biofrontera plans to launch the new indic...
09-14 13:26
Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $12.003 million whi...
08-13 20:54
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Biofrontera Inc. (NASDAQ: BFRI) announced it will report Q2 2026 financial results before the market opens on August 13, 2026. A conference call and webcast will be held at 10:00 a.m. ET the same day to discuss the results. U.S./Canada participants can dial 1-877-877-1275, while international participants can dial 1-412-858-5202. The webcast will be available at https://event.choruscall.com/mediaframe/webcast.html?webcastid=a2Bp6alz beginning 20 ...
08-05 20:15
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.
05-19 20:41
美股夜盘 | DirectBooking Technology Co., Ltd. Class A涨38.62%，WEX Inc.涨19.54%
P3 Health Partners Inc. Class A涨-17.63%；Artelo Biosciences Inc涨-14.67%；Lantern Pharma, Inc.涨-12.42%
05-18 08:05
Biofrontera目标2026年实现现金流盈亏平衡 毛利率剑指80%-85%
一季度业绩：营收增长17% 毛利率显著提升至80% Biofrontera近日公布2026年第一季度财报。数据显示，公司一季度产品营收达1010万美元...
05-15 03:09
Transcript: Biofrontera Q1 2026 Earnings Conference Call
On Thursday, Biofrontera (NASDAQ:BFRI) discussed first-quarter financial result...
05-14 23:39
